The U.S. Trustee and several insurance firms objected to confirmation of Johnson & Johnson’s proposed $10 billion bankruptcy plan, citing the U.S. Supreme Court’s 2024 ruling that dismantled Purdue Pharma’s opioid settlement.

The objections, filed ahead of a key Feb. 18 hearing on whether to confirm the Chapter 11 plan, cite the Supreme Court’s decision in Harrington v. Purdue Pharma. In that June 27 ruling, the high court, in a 5-4 ruling, invalidated nonconsensual releases in the $6 billion bankruptcy plan granted to Purdue’s founders, the Sacklers.